Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cipla
Mallinckrodt
US Department of Justice
Cantor Fitzgerald
Medtronic
Harvard Business School
Julphar
Chubb

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,557,993

« Back to Dashboard

Which drugs does patent 8,557,993 protect, and when does it expire?

Patent 8,557,993 protects LIVALO and is included in one NDA.

This patent has thirty-two patent family members in nine countries.
Summary for Patent: 8,557,993
Title:Crystalline forms of pitavastatin calcium
Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
Inventor(s): Van der Schaaf; Paul Adriaan (Hagenthal-le-Haut, FR), Blatter; Fritz (Reinach, CH), Szelagiewicz; Martin (Muenchenstein, CH), Schoening; Kai-Uwe (Oberwil, CH)
Assignee: Nissan Chemical Industries Ltd. (Tokyo, JP)
Application Number:13/664,498
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,557,993
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Drugs Protected by US Patent 8,557,993

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-001 Aug 3, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-002 Aug 3, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-003 Aug 3, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,557,993

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03405080Feb 12, 2003

Non-Orange Book US Patents Family Members for Patent 8,557,993

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,853,405 Crystalline forms of pitavastatin calcium ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,557,993

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 202004021379 ➤ Try a Free Trial
Australia 2004212160 ➤ Try a Free Trial
Canada 2513837 ➤ Try a Free Trial
Canada 2785954 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo
Fish and Richardson
Federal Trade Commission
McKinsey
Dow
US Department of Justice
Covington
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.